FDA approves Lundbeck's antidepressant Brintellix

Reuters

Sept 30 (Reuters) - The U.S. Food and Drug Administrationapproved Lundbeck's antidepressant Brintellix to treatadults with major depressive disorder.

The drug, which Lundbeck will co-market with Japanesepartner Takeda Pharmaceutical Co Ltd, will be availablein four doses.

Brintellix, like other antidepressants, will carry a boxedwarning alerting patients and doctors to an increased risk ofsuicidal thoughts and behavior in children, adolescents andyoung adults aged 18-24 during initial treatment.

The most common side effects reported by patients taking thedrug - generically known as vortioxetine - include nausea,constipation and vomiting.

Major depressive disorder is characterized by mood changesthat may interfere with a person's ability to carry out today-to-day activities. Symptoms also include increased fatigueand feelings of guilt or worthlessness.

Rates

View Comments